Role of peripheral pan-retinal photocoagulation in diabetic macular edema treated with intravitreal ziv-aflibercept [PDF]
Clinical Ophthalmology, 2019 Ahmad M Mansour,1,2 Khalil El Jawhari,3 J Fernando Arevalo4 1Department of Ophthalmology, American University of Beirut, Beirut, Lebanon; 2Department of Ophthalmology, Rafik Hariri University Hospital, Beirut, Lebanon; 3Medical School, Medical ...
Mansour AM, El Jawhari K, Arevalo JF
doaj +2 more sources
Safety of intravitreal ziv-aflibercept in choroido-retinal vascular diseases: A randomised double-blind intervention study. [PDF]
PLoS ONE, 2019 AIM:To evaluate the safety of 1.25mg and 2mg intravitreal ziv-aflibercept (IVZ) in Ghanaian eyes with choroido-retinal vascular diseases. DESIGN:Prospective, randomised, double blind, interventional study.
Imoro Zeba Braimah +5 more
doaj +2 more sources
Regression of Inflamed Pterygia by Frequent High-Dose Intralesional Ziv-Aflibercept [PDF]
Cornea, 2017 Purpose: Intralesional single low-dose vascular endothelial growth factor antagonists have traditionally failed in causing regression of pterygia. The current pilot study investigates the role of high-dose repeated intralesional ziv-aflibercept in causing regression of inflamed or recurring pterygia.
Mansour, Ahmad Mohammed Farid Mahmoud
openaire +3 more sources
Disease Control With FOLFIRI Plus Ziv-aflibercept (zFOLFIRI) Beyond FOLFIRI Plus Bevacizumab: Case Series in Metastatic Colorectal Cancer (mCRC) [PDF]
Frontiers in Oncology, 2019 Background: The prognosis of patients with metastatic colorectal cancer (mCRC) is poor, especially after failure of initial systemic therapy. The VELOUR study showed modestly prolonged overall survival (OS) with ziv-aflibercept plus 5-fluorouracil ...
Wafik S. El-Deiry +8 more
doaj +2 more sources
Use of ziv-aflibercept in diabetic macular edema in a Ghanaian population. [PDF]
Eye (Lond), 2022 To investigate the use of intravitreal ziv-aflibercept (IVZ) in Ghanaian patients with diabetic macular edema (DME).A retrospective study of patients with DME, who had been treated with IVZ (1.25 mg/0.05 ml), as part of routine clinical practice, on pro re nata basis between 2016 and 2018 who had a minimum follow-up of 6 months was retrieved and ...
Braimah IZ, Amoaku WM.
europepmc +3 more sources
Intravitreal Ziv-Aflibercept for Diabetic Macular Edema: 48-Week Outcomes
Ophthalmic Surgery, Lasers and Imaging Retina, 2018 BACKGROUND AND OBJECTIVE: To study the safety and efficacy of intravitreal injections of ziv-aflibercept (IVI-ZA) (Zaltrap; Sanofi-Aventis and Regeneron Pharmaceuticals, Tarrytown, NY) during a period of 48 weeks in patients with diabetic macular edema (DME).
Gabriel Costa, de Andrade +5 more
openaire +3 more sources
Osteonecrosis of the jaw associated with ziv-aflibercept. [PDF]
J Gastrointest Oncol, 2016 Medication-related osteonecrosis of the jaw (MRONJ) has been associated with medications that include bisphosphonates (BPs), denosumab, bevacizumab and sunitinib. Ziv-aflibercept is a recombinant human vascular endothelial growth factor (VEGF) receptor which has been used to treat patients with various advanced solid tumors.
Mawardi H +6 more
europepmc +4 more sources
Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment [PDF]
Cancer Immunology, ImmunotherapyMichael Manos +2 more
exaly +2 more sources
Retinal Toxicity of Intravitreal Injection of Ziv-Aflibercept in Albino Rabbits. [PDF]
Transl Vis Sci Technol, 2018 To evaluate retinal toxicity of ziv-aflibercept, a drug that had been approved for use for patients with colon cancer.Twenty-two albino rabbits were injected intravitreally with 0.1 mL of ziv-aflibercept solution into the experimental eye and 0.1-mL saline into the control eye. Twelve were used for electroretinogram (ERG) at 4-weeks follow-up.
Ramon D +5 more
europepmc +3 more sources
FOLFOX plus ziv‐aflibercept or placebo in first‐line metastatic esophagogastric adenocarcinoma: A double‐blind, randomized, multicenter phase 2 trial [PDF]
Cancer, 2019 James M Cleary +2 more
exaly +2 more sources